Olmesartan
Signals from filings dated January 2026 – October 2026 · Last checked 7 Nov 2026
Supply outlook
⇅ MIXEDIn the filings we track: 1 plant adding this molecule, 1 exit signal, 0 intermediate projects.
Signals
Nanoarray Biosciences Pvt. Ltd.
Plot 46-47, Suvas Global Industrial Hub, Moraiya, Sanand, Ahmedabad, Gujarat
- ✓ Terms of reference
- ✓ Public hearing · 30 Oct 2026
- Next: clearance
- Consent to operate
- DMF / CEP
Listed in Group E (17 products, and/or): 36 t/yr shared across the group. Greenfield API unit, 283.2 t/yr in total. Public hearing held 30 Oct 2026. Source: EIA executive summary, GPCB
Fusion Health Care Pvt. Ltd.
Sy. No. 667, Bhiknoor, Kamareddy, Telangana
- ✓ Terms of reference
- ✓ Public hearing · 7 Jan 2026
- Next: clearance
- Consent to operate
- DMF / CEP
Filed as olmesartan medoxomil. Capacity 166.67 → 120 kg/day (-46.67). Expansion of an approved API unit still under construction (EC 2021; taken over by Fusion Health Care in 2023). Worst case 6 products run at once; site total 1,000 to 2,420 kg/day. Public hearing held 7 Jan 2026. Source: EIA executive summary, TGPCB
Who makes Olmesartan today: 68 listings
Current manufacturers with US DMF and CEP status, plant addresses and contacts.
| Manufacturer | Country | US DMF | CEP | Contact |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | Israel | ✓ | — | In database |
| + 67 more listings in api-fdf.com → | ||||
Three examples from the api-fdf.com database, refreshed weekly. Plant addresses and contacts are shown in the database.
Follow Olmesartan
Get an email when a new filing adds, cuts or moves this molecule to the next stage.